Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences

Executive Summary

GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.

You may also be interested in...



Evotec Drug Development Strategy Offers Little Downside, Big Upside

Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.

Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal

Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.

Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS055032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel